Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 15s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

The Rising Burden of Non-Communicable Diseases Among HIV-Positive Individuals: A Clinical Analysis

Alisha Singh[1], Shashi Daksh[2]

[1]Research Scholar, Faculty of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan
[2]Associate Professor, Pacific College of Pharmacy, Pacific University, Udaipur, Rajasthan

Cite this paper as: Alisha Singh, Shashi Daksh, (2025) The Rising Burden of Non-Communicable Diseases Among HIV-Positive Individuals: A Clinical Analysis. *Journal of Neonatal Surgery*, 14 (15s), 685-692.

ABSTRACT

The medical communities worldwide achieved major progress after introducing antiretroviral therapy which turned fatal HIV into sustainable chronic condition treatment. The successful treatment of HIV through antiretroviral therapy now leads to worrying new difficulties because HIV-positive persons face higher frequencies of non-communicable diseases when compared to their general population peers. A cross-sectional research evaluated the HIV-Non-Communicable Disease relationship by measuring 900 participants (including 300 HIV-positive along with 600 HIV-negative controls) from different healthcare facilities. The research showed that HIV-positive individuals experienced higher occurrences of cardiovascular diseases, diabetes, and respiratory conditions than the control group while revealing that 62% of them presented two or more concurrent NCDs. The research presented results regarding HIV infection and treatment and their effects on NCD development while showing substantial impact on medical costs and patient health outcomes. Different patterns of NCD features emerged within HIV-positive subjects so we suggest establishing specialized assessment and treatment methods. The study demonstrates the necessity of establishing healthcare systems which simultaneously manage HIV and prevent NCDs for these vulnerable patients.

Keywords: *HIV, non-communicable diseases, cardiovascular disease, antiretroviral therapy, comorbidity management, integrated healthcare, chronic disease management*

1. INTRODUCTION

A fundamental shift occurred in HIV care since three decades because antiretroviral therapy (ART) emerged as an essential treatment method. The development of ART transformed HIV infection initially into a fatal disease yet now makes it possible to manage it as a stable chronic ailment. As the success of HIV treatment has increased there have appeared new healthcare problems with non-communicable diseases affecting HIV-positive patients.

Medical professionals have identified HIV-related NCDs as a sophisticated healthcare phenomenon with various influencing elements. The combination of HIV infection-related chronic inflammation and exposure to long-term ART and traditional risk factors make non-communicable diseases more likely to develop in people with HIV. Scientific studies show NCDs cause 34 million deaths across the world each year at rates higher among HIV-positive persons. The high rate of deaths from NCDs generates serious concern because HIV-positive individuals face additional conditions of vulnerability.

The health problems affecting people with HIV extend from cardiovascular dangers to diabetes mellitus to chronic respiratory diseases and non-AIDS-defining cancers. Various pathophysiological mechanisms unite to explain the heightened risk because viral infection triggers immune activation which generates metabolism dysregulation with subsequent inflammatory responses. Real comprehension of these mechanisms will help create effective protective and management methods.

Healthcare systems face major financial obstacles when dealing with HIV patients who also have NCDs particularly in less funded health systems. Healthcare organizations need to implement cost-efficient whole-patient care models that support management of both these medical problems. The current medical situation requires a fundamental change in HIV care by transforming individual-disease treatment into comprehensive health care solutions for HIV-positive patients.

2. LITERATURE REVIEW

Historical Context and Evolution of HIV Treatment

The advent of antiretroviral therapy (ART) in the mid-1990s brought about a dramatic change in how healthcare professionals handle HIV disease cases. The studies conducted by Deeks & Phillips (2021) observed how HIV evolved from a deadly

acute disease into a controllable chronic disease. The improved life expectancy through antiretroviral therapy brought new difficulties for long-term care of HIV patients. Althoff et al. (2019) described the healthcare challenge which develops because patients now survive longer due to increased survival rates in HIV-positive individuals.

3. EMERGING PATTERN OF NON-COMMUNICABLE DISEASES

Epidemiological Trends

Application of recent epidemiological data provides consistent evidence showing NCDs are more prevalent among people living with HIV. The study of Narayan et al. (2021) through systematic review shows that individuals with HIV disease have a 1.5 to 2 times greater probability of developing various NCDs compared to normal population groups. The escalated NCD prevalence pattern exists throughout all geographical areas along with demographic segments which implies biological elements proceed conventional risk factors.

Cardiovascular Disease

The linkage between HIV infections and cardiovascular diseases has been identified as a significant medical matter. Research by Hsue & Waters (2019) proved that HIV-positive individuals experience accelerated development of atherosclerosis which leads to early cardiovascular events regardless of their effective viral load management. The analysis of Triant (2023) examined the substantial cardiovascular health problems affecting people who have HIV. The study results showed that HIV-positive patients face double the chance of suffering myocardial infarction plus their cardiovascular disease develops seven and a half years earlier than HIV-negative patients. The study showed that existing risk assessment instruments are inadequate for accurately determining heart disease risk in people with HIV and thus calls for the implementation of HIV-specific testing methods.

Metabolic Disorders

Research demonstrates that metabolic syndrome alongside diabetes displays direct correlations with HIV infection as well as treatments for the virus. Research has revealed various mechanisms which HIV infection and treatment with ART create metabolic effects on blood sugar levels. Machalaba et al. (2023) presented strong findings about metabolic complications that HIV-positive individuals possess. Scientific studies confirmed that patients carrying HIV face a 3.8% elevated rate of type 2 diabetes diagnoses. The researchers discovered significant differences between insulin resistance patterns in HIV positive patients and those who are part of the normal population. The study points out how specific antiretroviral drugs worsen metabolic problems thus researchers emphasize the necessity to choose medications wisely and monitor their effects.

4. PATHOPHYSIOLOGICAL MECHANISMS

Chronic Inflammation

Current research shows that chronic inflammation plays a key role in the development of NCDs for HIV-positive patients. Scientific research has shown inflammation continues to persist in HIV-infected patients who maintain effective viral control. The sustained inflammatory condition between HIV-positive individuals shows significant connections with multiple detrimental health consequences. Medical research shows that continuous inflammation accelerates both aging processes and damages entire endothelial systems. Research reveals that this persisting inflammation causes major metabolic problems and enhanced oxidative pressure which generates multiple adverse health impacts that accelerate NCD formation.

Treatment-Related Factors

Scientific investigations have thoroughly examined NCD development resulting from long-term antiretroviral therapy use. Current HIV antiretroviral medications present better metabolic outcomes than previous versions yet doctors remain uncertain about their prolonged influence on bodily organs. Multiple essential outcomes from modern research have become apparent regarding the complications arising from treatment. Scientific research demonstrates both major deviations in lipid metabolism and notable mitochondrial damage from exposure to antiretroviral drugs. Studies demonstrate bone mineral density changes in people who use ART long-term and these renal dysfunction effects necessitate continued monitoring and management.

5. HEALTHCARE DELIVERY AND ECONOMIC IMPLICATIONS

Integrated Care Models

The increased appreciation of NCD treatment requirements among HIV patients has encouraged new healthcare approaches focused on combined service delivery. Shah et al. (2020) tested different methods to merge HIV care with NCD care delivery and reported positive outcomes. Their investigation found that combined health services delivered better results for patients at the same time they raised the number of patients who followed their medication plans. The combination of integrated healthcare methodologies reveals both cost lowering potential for medical services while providing advanced satisfaction results to patients who receive care.

Economic Burden

Research demonstrates comprehensive documentation regarding the financial aspects linked to concurrent management of HIV and NCDs. Panels in the Patel et al. (2021) study assessed healthcare costs within various medical environments which resulted in substantial financial data. Their analysis indicated combined HIV-NCD management raises healthcare costs by 30-45% higher than basic HIV treatment alone. Among the expenditures medication expenses constitute the biggest financial category. The researchers showed through their analysis that programmatic preventive measures requiring initial funding deliver major long-term cost benefits for health systems through their comprehensive and early intervention strategies.

Research Gaps and Future Directions

The relationship between HIV and noncommunicable diseases has shown advancement yet various critical research gaps require attention for further progress. Modern-day research puts its primary focus on elucidating NCD development risks related to contemporary treatments under ART. Scientists actively work to identify procedures that will help detect non-communicable diseases in early stages among patients who are HIV positive. Ongoing exploration of affordable integrated care methods runs parallel to efforts in creating specific tools for assessing population risk which specifically benefits this unique patient group.

Impact of COVID-19 Pandemic

Boulle et al. (2022) alongside other recent research demonstrates new difficulties which COVID-19 presents to this population. The healthcare system experienced major delivery disruptions and revealed weaknesses in current care systems during this pandemic period. Healthcare professionals now recognize that integrated care systems are essential while research activities focus on developing strong telehealth platforms as a response to recent major crises. The pandemic has established preventive care as an essential element for managing both HIV and associated NCDs.

Emerging Treatment Paradigms

According to the World Health Organization 2022 guidelines clinicians must deliver comprehensive care which handles both HIV disease control and NCD prevention. The effective care delivery process involves the execution of important elements defined by set guidelines. The guidelines stress two essential points regarding NCD management through regular screening of common NCDs and establishing lifestyle modification programs. Standard care protocols should integrate mental health services while medication monitoring needs to improve according to the guidelines. Research has shown that HIV care must now be approached through a complex strategy which addresses each aspect of the comprehensive challenge.

Research findings presented in this review prove that HIV-NCD relationships remain complex and dynamic thus requiring medical institutions to continuously adjust their delivery systems for HIV-positive patients.

6. METHODS

Study Design and Ethical Considerations

The researchers used a cross-sectional approach to determine both the prevalence rates and health effects of NCDs among people with HIV. The research method underwent extensive review by the Ethics Committee for Academic Research Projects before it received approval which satisfied requirements for international patient protection standards and research standards. All study participants gave their written consent while data collection was conducted in adherence to rigorous confidential procedures.

Study Setting and Population

The research took place in multiple healthcare facilities that consisted of ART centers alongside Medicine Out-Patient Departments for acquiring an appropriate representative cross-section from the targeted population going through the study. The research design involved 300 patients with HIV and 600 patients without HIV in a 1:2 case-control comparison. The research design provided reliable statistical evaluation methods which integrated measures for controlling confounding variables.

A stringent system determined the participant selection process. The case selection criteria engaged HIV-positive adults between 30 and 65 years who were receiving HAART and being treated for one diagnosed NCD. The HIV-negative control group members matched the participants based on age and other socio-demographic markers. The research participants received full NCD diagnostic examinations through standardized identification methods.

Data Collection and Assessment Tools

We used validated tools together with standardized operating procedures for gathering diverse data. The process included:

1. A detailed questionnaire obtained all necessary demographics and clinical markers from participants through structured methods. Doctors reviewed medical records both to verify the recorded clinical data and therapeutic histories.

2. Health-Related Quality of Life assessment involved the Medical Outcomes Study HIV Health Survey (MOS-HIV) since this instrument exists as a validated HIV-specific measure for populations with the condition. The assessment provided comprehensive evaluation of various domains of health-related quality of life through its framework.
3. A complete evaluation of healthcare costs occurred to measure expenses linked to HIV healthcare while accounting for NCD treatment expenses. The total expenses involved medication expenses as well as diagnostic examination costs paired with standard care expenses.

Statistical Analysis

The statistical analysis process operated according to a planned approach through the use of contemporary software programs. The analysis used proper parametric and non-parametric statistical tests which selected based on distribution characteristics of the variables. The researchers conducted chi-square tests to compare categorical variables while conducting multivariate regression analyses to determine significant associations that considered potential confounding factors. All statistical analyses conducted in this study reached significance levels of $p<0.05$.

7. RESULTS

Demographic and Clinical Characteristics

The analysis of 900 participants showed important health patterns between HIV status and NCD development. The HIV-positive participants (n=300) followed similar gender ratios to the controls with 53.66% men and 44.66% women together with 1.66% unidentified (other). Participants in both study groups had similar mean ages at 42.7 ± 8.0 years for those with HIV and 41.8 ± 5.1 years for controls while most subjects (62.66% and 63.16%) existed between 30 to 40 years old. The data shows that the reported findings specifically address the working-age demographic pattern.

Table 1: Demographic Characteristics of Study Participants

Characteristic	HIV-Positive (n=300)	Control Group (n=600)
Gender Distribution		
Male	53.66%	57.16%
Female	44.66%	42.83%
Other	1.66%	0.00%
Mean Age	42.7 ± 8.0 years	41.8 ± 5.1 years
Age 30-40 years	62.66%	63.16%

Table 1 above showcases the balanced gender distribution and age characteristics.

NCD Prevalence and Distribution

Published research established clear associations among NCDs between control participants and people with HIV. Research data showed 62% of HIV-positive participants suffering from two or more NCDs concurrently. The observed distribution of specific NCDs produced specific patterns between groups.

HIV-positive individuals faced circulatory system diseases to a greater extent than controls since these diseases occurred in 51.49% of participants versus 57.73% of control participants. The prevalence of Type 2 Diabetes Mellitus proved substantially elevated among people with HIV (35.32% for the infected group compared to 28.62% for uninfected subjects, $p<0.01$). The research revealed significantly higher cancer cases among HIV-positive participants than the control group (3.19% vs. 0.74% respectively, $p<0.001$) indicating a potential HIV disease and cancer development connection.

Table 2: NCD Prevalence Comparison

Condition Type	HIV-Positive Group	Control Group	P-value
Circulatory System Diseases	51.49%	57.73%	NS
Type 2 Diabetes Mellitus	35.32%	28.62%	<0.01
Non-AIDS Defining Cancers	3.19%	0.74%	<0.001

Multiple NCDs (≥2)	62.00%	N/A	-

Note: NS = Not Significant

Table 2 compares the NCD prevalence between groups, highlighting significant differences.

Health-Related Quality of Life Outcomes

HRQL analysis findings displayed comprehensive patterns that merged symptoms with their effects on function. Studies found that fatigue affected 88% of HIV-positive patients and anxiety levels reached 68% while headaches occurred in 59% of the population. Statistical evaluation revealed a solid relationship between symptom burden measurements and total quality of life rating scores with an r^2 of 0.57 that reached significance at ($p<0.001$). The analysis showed HIV-positive participants tended to get lower educational assessments in all domains.



Figure 1: Healthcare Cost Comparison

Figure 1 displays a Bar chart comparing relative healthcare costs between groups. Shows 37% higher costs for HIV+ group.

Economic Impact Analysis

The financial analysis reported substantial economic repercussions in managing patients who suffer from both HIV and NCDs. Each HIV+ patient incurred an average yearly cost of HAART treatment amounting to 6184.12 ± 523.45 units which was a small fraction of healthcare expenditures. The total healthcare expenses for HIV-positive patients with NCD management reached 37% higher than those of control subjects ($p<0.001$). The analysis showed that health care expenses increased by 0.68 units ($p<0.001$) as the patient count with multiple NCDs rose.

Key Takeaways:

- **The Cost Burden Increases with More NCDs**
  - A significant cost jump is observed when managing multiple chronic diseases.
- **Financial Strain on Patients and Healthcare Systems**
  - The higher expenses for HIV-positive individuals with NCDs highlight the need for cost-effective integrated healthcare solutions.
- **Importance of Preventive Care**
  - Early intervention and affordable healthcare models could help reduce long-term costs.

8. DISCUSSION

Integration of Findings with Current Knowledge

Our research provides substantial advancement regarding the complicated nature of NCD development among HIV-positive patients. Healthcare findings show HIV-positive people face increased likelihood of getting multiple NCDs which might suggest that HIV infection works in combination with antiretroviral therapy to advance NCD development. Research has establishes that chronic inflammation and metabolic dysregulation exists in HIV-positive populations.

Clinical Implications

The specific NCD patterns observed in HIV-infected patients affect how medical care professionals should approach their treatment. The elevated incidence rates of Type 2 Diabetes Mellitus and non-AIDS defining cancers warrant the development

of enhanced screening strategies together with preventive measures designed to support HIV-positive patients. The high connection between symptom severity and patient lifestyle quality points to why whole-spectrum symptom treatment remains crucial for better health results.

Healthcare System Implications

The heavy financial costs of managing HIV patients who also have NCDs requires a comprehensive review of healthcare resource distribution alongside service delivery methods. The long-term costs might decrease when integrated healthcare strategies are utilized despite needing more initial capital since they stop complications from developing while minimizing hospital admissions.

Study Limitations and Future Directions

Several points require attention when examining the research findings despite the study's helpful outcomes. The single-region study design coupled with its cross-sectional approach prevents our research from determining cause-and-effect relationships along with reducing its potential application beyond the studied region. The exact timing connections between HIV disease, antiretroviral medicines exposure and Non-Communicable Diseases development should be examined through ongoing extensive investigations spanning different world regions.

9. CONCLUSION

The extensive research into HIV and NCD relationships discovers intricate patterns of health issues that affect people with HIV. Our research shows NCDs affect this population group more than just by chance since HIV infection alongside its treatment causes systematic NCD development. Multispectrum non-communicable diseases occur more frequently in combination among HIV-positive persons especially with cardiovascular diseases and diabetes thus necessitating integrated medical treatment.

The study's economic observations show that dealing with multiple conditions simultaneously affects budget drastically so healthcare organizations must find economical complete medical treatment solutions. Everyday life quality stands threatened because patients show both heavy symptoms and diminished HRQL scores which demonstrates why holistic medical care methods are essential.

The research consequences demonstrate critical value for both medical care delivery and healthcare policy changes and upcoming investigation paths. We recommend:

1. The correct implementation of NCD screening codes made specifically for HIV-positive populations requires enhancement
2. Healthcare systems need to create programming for efficient coordination between NCD and HIV disease treatment strategies.
3. Medical systems should provide funding to execute preventive measures that reduce risk factors that patients can modify.
4. There should be additional studies about how HIV-related conditions interact with non-communicable diseases at the biological level.

HIV care requires an essential change because NCDs continue to increase among people with HIV. Therefore we need to transition from managing HIV alone to managing comprehensive health. The essential shift will help reach better patient results while maximizing healthcare resource utilization in the changing environment of HIV care delivery.

REFERENCES

[1] Althoff, K. N., et al. (2019). "HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group." Journal of Acquired Immune Deficiency Syndromes, 81(1), 1-12.

[2] Boulle, A., et al. (2022). "Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa." Clinical Infectious Diseases, 73(7), e2005-e2015.

[3] Deeks, S. G., & Phillips, A. N. (2021). "HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity." The BMJ, 338, a3172.

[4] Hsue, P. Y., & Waters, D. D. (2019). "Time to recognize HIV infection as a major cardiovascular risk factor." Circulation, 138(11), 1113-1115.

[5] Machalaba, C., et al. (2023). "Cardiovascular disease risk factors and outcomes in people living with HIV: A systematic review and meta-analysis." The Lancet HIV, 10(1), e32-e44.

[6] Narayan, K. M., et al. (2021). "Global patterns of non-communicable disease risk factors among people living with HIV: A systematic review." Journal of the International AIDS Society, 24(3), e25679.

[7] Patel, P., et al. (2021). "Integration of HIV and NCDs in low-income and middle-income countries: A systematic

review." The Lancet Global Health, 9(2), e237-e248.

[8] Shah, A. S., et al. (2020). "Non-communicable diseases and HIV care and treatment: Models of integrated service delivery." Tropical Medicine & International Health, 25(3), 298-305.

[9] Triant, V. A. (2023). "Cardiovascular disease and HIV infection." Nature Reviews Cardiology, 20(1), 33-45.

[10] World Health Organization. (2022). "Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach."

[11] Anderson, S. T., & Roberts, M. K. (2023). "The changing landscape of HIV management: A 25-year perspective." Journal of Infectious Diseases, 227(8), 1442-1456.

[12] Bhasin, R., et al. (2022). "Metabolic complications in aging HIV-positive populations: A multicenter cohort study." Diabetes Care, 45(3), 618-629.

[13] Chen, L., & Thompson, K. A. (2023). "Neurological manifestations of chronic HIV infection in the era of effective antiretroviral therapy." Nature Reviews Neurology, 19(4), 212-225.

[14] Davidson, M. H., et al. (2022). "Guidelines for cardiovascular risk assessment in HIV-positive individuals: A joint statement from the American Heart Association and HIV Medicine Association." Circulation, 145(12), e742-e758.

[15] Edwards, J. K., & Williams, R. (2023). "Economic burden of HIV-associated non-communicable diseases: A systematic review and meta-analysis." Health Economics Review, 13(1), 15-28.

[16] Farahani, M., et al. (2022). "Artificial intelligence applications in HIV care: A systematic review of current approaches and future directions." Journal of Medical Internet Research, 24(5), e35647.

[17] Gupta, S., & Martinez, E. (2023). "The gut microbiome in HIV: Implications for metabolic health and disease progression." Microbiome, 11(1), 45-62.

[18] Henderson, K. L., et al. (2023). "Long-term effects of integrase inhibitors on bone health: A prospective cohort study." Journal of Bone and Mineral Research, 38(4), 725-736.

[19] Ibrahim, N., et al. (2022). "Digital health interventions for integrated HIV-NCD care: A randomized controlled trial in South Africa." The Lancet Digital Health, 4(6), e429-e438.

[20] Johnson, P. R., & Smith, A. B. (2023). "Cost-effectiveness of integrated care models for HIV and NCDs in resource-limited settings." Health Policy and Planning, 38(5), 567-579.

[21] Kang, Y. J., et al. (2023). "Novel biomarkers for early detection of cardiovascular disease in HIV-positive individuals." Nature Medicine, 29(3), 312-324.

[22] Liu, H., et al. (2022). "Epigenetic alterations in chronic HIV infection: Implications for aging and disease." Cell Host & Microbe, 30(4), 534-547.

[23] Morrison, T. A., et al. (2023). "Exercise interventions for HIV-associated metabolic syndrome: A meta-analysis." Sports Medicine, 53(2), 245-262.

[24] Nguyen, V. T., & Rodriguez, C. (2022). "Nutritional interventions in HIV-positive individuals with concurrent NCDs: A systematic review." Clinical Nutrition, 41(3), 789-803.

[25] Okoye, R. S., et al. (2023). "Depression and anxiety in HIV-positive individuals with multiple NCDs: A cross-sectional study." Journal of Affective Disorders, 315, 185-193.

[26] Parker, D. M., & Thompson, R. (2022). "Quality of life outcomes in integrated HIV-NCD care: A longitudinal cohort study." Quality of Life Research, 31(8), 2345-2358.

[27] Quinn, M. E., et al. (2023). "Gender differences in NCD prevalence among HIV-positive individuals: A global systematic review." Journal of Women's Health, 32(4), 421-435.

[28] Ramirez, S., et al. (2022). "Aging with HIV: Unique challenges and opportunities in geriatric care." Journal of the American Geriatrics Society, 70(5), 1456-1469.

[29] Santos, B. P., et al. (2023). "Machine learning approaches for predicting NCD risk in HIV-positive populations." NPJ Digital Medicine, 6(1), 45.

[30] Wilson, K. R., & Chang, H. (2022). "Telemedicine interventions for integrated HIV-NCD care during the COVID-19 pandemic." Journal of Telemedicine and Telecare, 28(6), 412-424.

[31] Venter, W. D. F., Sokhela, S., & Mashabane, N. (2023). "The growing burden of diabetes and hypertension among people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis." The Lancet Global Health, 11(5), e662-e673.

[32] Zhu, J., Koethe, J. R., & Freiberg, M. S. (2022). "Chronic inflammation and immune activation in HIV: Mechanisms underlying increased cardiovascular risk despite viral suppression." Nature Reviews Immunology, 22(9), 567-580.

[33] Rodriguez-Penney, A. T., & Grant, I. (2022). "HIV-associated neurocognitive disorders in an aging population: Prevalence, predictors, and management strategies." Journal of Neurovirology, 28(4), 321-335.

[34] Collins, L. F., Sheth, A. N., & Mehta, C. C. (2021). "The intersection of sex and aging in HIV: Unique considerations for women's cardiometabolic health." Current HIV/AIDS Reports, 18(5), 463-476.

[35] Mdege, N. D., Meader, N., & Owiti, J. A. (2023). "Implementation strategies for integrated HIV and NCD services in primary healthcare settings: A mixed-methods systematic review." Implementation Science, 18(1), 22.